Page 4 - Targeted Augmentation News Today

– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 ini...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 15, 2023, the company granted stock options to purchas...

- Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 - - Company plans to initiate a pivotal study... | May 4, 2023

– Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 –– Company plans to initiate...

- Company advancing second TANGO ASO into the clinic - - STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve

- Dosing anticipated to start in the coming weeks - - Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in... | March 15, 2023

Research from the University of Virginia School of Medicine suggests how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, and potentially prolong survival for people with the condition.

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) –– ADOA is the most common inherited optic nerve disorder –BEDFORD, Mass.--(B...